BIO-LES Advanced Business Development Course Faculty

  • Recommend
  • Tweet
  • Print
  • Email

2014 Advanced Business Development Course Faculty

This page shows the 2014 Advanced Business Development course faculty members. We also offer a Business Development Fundamentals course- click here to view the Business Development Fundamentals course faculty members.

Joseph S. Dillon, MBA, CLP
President & CEO, Dillon Capital Strategies

Joseph S. Dillon, MBA, CLP, is President & CEO of SynerPhysics, Inc. and President of Dillon Capital Strategies, the strategy and business analytics advisory arm of SynerPhysics. Mr. Dillon is a seasoned pharmaceutical executive with over 20 years of experience. He has extensive experience in global pharmaceutical business planning and analysis, corporate finance, M&A, licensing, and technology valuations. Over the course of his career, Mr. Dillon has screened thousands of opportunities, valued over 300 deals and has been involved in over 40 closed transactions. Prior to forming SynerPhysics and DillonCapital Strategies, Mr. Dillon held senior positions in two pharmaceutical management consulting firms, most significantly was as Senior Vice President, Head of Corporate Development Services and Valuations for The Mattson Jack Group (now Kantar Health). Other previous positions include CEO, President, and Director of The Pharmaceutical Development Center, a pharmaceutical developer and manufacturer; Executive Vice President and CFO of Vail Banks Inc., a multi-bank holding company; CFO and Treasurer of Oread Inc., a contract pharmaceutical developer and manufacturer; and corporate positions with predecessor companies of Sanofi. Mr. Dillon is Past-Chairperson of the Licensing Executive Society Life Sciences Sector Leadership Committee and Past-Chairperson of its Education Committee. He is a veteran speaker at BIO, LES, WBR, EBD, and other prominent industry organization events. Mr. Dillon holds an M.B.A. in International Finance, a bachelors in Finance and has earned the Certified Licensing Professional (CLP) designation.

Patrick Duxbury
Partner, Wragge & Co LLP

Patrick Duxbury is a Partner at Wragge & Co LLP and head of their Life Sciences Team. Patrick was originally a microbiologist and geneticist before re-qualifying as a lawyer in 1993 with first class honors. Patrick specializes in all aspects of transactional intellectual property law in the life sciences sector.

Recent transactions include several M&A transactions and licensing and collaboration deals for biotech and pharmaceutical company clients such as arGEN-X, AstraZeneca, Astellas, MedImmune, Astex Therapeutics, Chroma Therapeutics, Eisai, GSK, Heptares Therapeutics, PanGenetics and others. Examples of transactions include:

  • Acting for Cambridge Antibody Technology Group (and now MedImmune) over the last ten years on numerous license and collaboration deals including transactions with Amgen, Dyax, Micromet, Wyeth and Merck. Patrick was involved in advising MedImmune on the restructuring of its TGF Beta antibody collaboration with Genzyme and its deals with Xenome, Evotec, Amgen and Catalyst BioSciences Inc. Most recently he acted for MedImmune on the widely publicized in-license of the Phase III antibody, Tremelimumab, from Pfizer
  • Acting for Astex Therapeutics on all of its significant transactions including its widely publicized license and collaboration deals with AstraZeneca, Novartis, J&J and GSK and its recent merger with SuperGen Inc.
  • Acting for the Japanese pharmaceutical company Eisai on its acquisition of the European rights to the intrathecal painkiller, Prialt, from Elan and the license of the European rights to NeuroBloc® from Solstice Neurosciences Inc.
  • Advising PanGenetics BV in connection with the $190m disposal of its PG110 antibody program to Abbott and Chroma Therapeutics on its $1 billion collaboration with GSK.
  • Patrick advised Astellas on its Phase III product in-license from Basilea Pharmaceuticals.
  • Acting for GSK on the creation of Convergence Pharmaceuticals and most recently Autifony Therapeutics (both funded by SV Life Sciences).

Kenneth Krisko
Partner, Cooley LLP

Kenneth Krisko is a partner in the Cooley Business department. He joined the Firm in 2000 and splits his time between the Reston and Boston offices.

Mr. Krisko's practice focuses on the representation of public and private life sciences companies in a broad range of commercial and corporate finance matters. He advises clients regularly with respect to complex commercial transactions designed to maximize the value of pharmaceutical products and technology assets, including technology licenses and acquisitions, research and development collaborations, distribution and manufacturing agreements, and profit-sharing and co-promotion arrangements. He also regularly counsels clients on a wide array of corporate and securities matters, including spin-outs, private financings, mergers and acquisitions, public offerings and corporate governance. He works closely with his clients to understand each client's business and strategic objectives and to structure and negotiate transactions to meet those objectives.

Mr. Krisko has been a guest speaker on strategic partnering and corporate issues affecting life sciences companies at various conferences. Mr. Krisko also is an Adjunct Professor of Law at the Georgetown University Law Center where he teaches a course on emerging company legal issues and venture capital finance.

Ken received a J.D. from the University of Virginia School of Law in 1995, where he was a member of the Virginia Law Review. Mr. Krisko received a B.S. in Aerospace and Ocean Engineering from Virginia Tech in 1987. Prior to joining Cooley, Mr. Krisko was an associate with Wiley, Rein & Fielding in Washington, D.C. Prior to attending law school, Mr. Krisko worked as an engineer for the Department of the Navy.

Lesley Stolz, Ph.D.
Transactions Team, Johnson & Johnson Innovation

Dr. Stolz has 17 years of business and corporate development experience working for companies that are both technology platform and therapeutics focused. She is currently working with Johnson & Johnson Innovation in the California Center on their transactions team. Previous to J&J, Dr. Stolz was most recently EVP of Corporate Development for BioTime, Inc. Prior to BioTime, she was Vice President Business Development at Sutro Biopharma, Inc. where she was responsible for all aspects of collaborations as well as fund raising during a three year period where the company entered into strategic collaborations and completed a significant Series C raise of $36.5M. Prior to Sutro Biopharma, Inc, she was with Sunesis Pharmaceuticals where she was Vice President Corporate & Business Development. Earlier in her career, she served as Senior Director, Business Development for Aerovance, Inc. where she led efforts to partner the company’s Phase 2 asset for uncontrolled asthma. Lesley was Senior Director, Business Development for GPC Biotech AG of Germany from 2002 to 2006. She also served in senior management positions at Cell Genesys, Discovery Partners International and Axys Pharmaceuticals. Dr. Stolz received her Ph.D. in chemistry, and conducted postdoctoral research at Harvard Medical School’s Department of Biochemistry and Molecular Pharmacology.